Miami, Florida 33136


Purpose:

The purpose of this research study is to evaluate the use of NAC in the treatment of anosmia (a loss of the sense of smell). This drug is already approved by the Food and Drug Administration (FDA) for oral or pulmonary (lung) inhaled use for other medical conditions. However, there is research evidence that the medication may promote nerve recovery (help nerves work better after they are damaged). Since anosmia involves nerve problems, we believe the nasal spray may help treat anosmia. The medication has been in use for many years for other conditions, without safety problems.


Criteria:

Inclusion Criteria: - adults at least 18 years of age with documented microsmia or anosmia by University of Pennsylvania Smell Identification Test. - patients must have no evidence of active sinonasal disease by nasal endoscopy or CT or MRI - negative CT or MRI Exclusion Criteria: - adults unable to consent - individuals who are not yet adults (infants, children, teenagers) - pregnant women, prisoners, employees or subordinates, - patients with known sensitivity to NAC or severe asthma - patients with sinus or central disease on CT or MRI imaging.


NCT ID:

NCT02481609


Primary Contact:

Principal Investigator
Bradley J Goldstein, MD, PhD
University of Miami

Constanza H Pelusso, MD
Phone: 305-243-7102
Email: cpelusso@med.miami.edu


Backup Contact:

N/A


Location Contact:

Miami, Florida 33136
United States

Constanza H Pelusso, MD
Phone: 305-243-7102
Email: cpelusso@med.miami.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.